Breast Journal最新文献

{"title":"Integrating Serum Lipid Biomarkers Into Machine Learning for the Differential Diagnosis of Breast Nodules","authors":"Longmei Chen,&nbsp;Yuzhen Du,&nbsp;Wanchao Liu","doi":"10.1155/tbj/2642494","DOIUrl":"https://doi.org/10.1155/tbj/2642494","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To develop and validate an interpretable machine learning (ML) model for predicting malignant risk in patients with breast nodules using serum lipid biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 899 patients with breast nodules (236 malignant) admitted between March 2022 and December 2024. Patients were randomly assigned to a training cohort (<i>n</i> = 630) and an internal validation cohort (<i>n</i> = 269) at a 7:3 ratio. Baseline clinical and laboratory data were collected upon admission. Following feature selection via LASSO regression, the predictive performance of 8 ML algorithms was evaluated and compared using receiver operating characteristic (ROC) curves. The optimal model’s performance was further corroborated using an independent temporal validation cohort of 190 patients (admitted Jan–Aug 2025). Model interpretability was addressed using SHapley Additive exPlanations (SHAP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nine key predictors were identified from 20 candidates by Lasso regression and clinical expertise. The random forest (RF) model outperformed other algorithms, achieving areas under the curve (AUC) values of 0.789, 0.782, and 0.825 for the training, internal validation, and temporal validation cohorts, respectively. Hosmer–Lemeshow tests (<i>p</i> &gt; 0.05) indicated high calibration between the predicted and observed risks. SHAP importance analysis revealed Fer, age, and CEA to be the top three predictive factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The RF model based on serum lipid biomarkers serves as a robust, noninvasive tool for assessing breast cancer risk, showing significant potential for clinical decision support in screening programs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/2642494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"rs2357322 and rs17726078 Contribute to Breast Cancer Risk by Regulating DLX2 Expression","authors":"Xin-Xin Zhang,&nbsp;Hao Guo,&nbsp;Hai-Yan Li,&nbsp;Xi-Ting Zhou,&nbsp;Hong-Li Song,&nbsp;Jiang-Wei Xu,&nbsp;Yu-Hang Fu,&nbsp;Ru-Hui Tian,&nbsp;Ru Jiang,&nbsp;Chun-Chun Liu,&nbsp;Chang Sun","doi":"10.1155/tbj/3096873","DOIUrl":"https://doi.org/10.1155/tbj/3096873","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Breast cancer is the most abundant cancer type in female. Genome-wide association study suggests that rs2016394, one SNP at the intron of DLX2 divergent transcript (<i>DLX2-DT</i>), is significantly associated with this disease. Through 1000 genomes project data analysis, it is observed that another three SNPs, rs743605, rs2357322, and rs17726078, show strong linkage disequilibrium with rs2016394. However, the functional SNP(s) and mechanism are still unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Functional genomics effort was performed for this locus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Through luciferase assay, it is disclosed that rs743605 and rs2016394 are not with the ability to alter gene expression. In contrast, rs2357322 and rs17726078 alleles present significantly different luciferase expression, thus suggesting that these two SNPs are functional mutations. Chromosome conformation capture indicates that <i>DLX2</i> (distal-less Homeobox 2) can interact with the <i>cis</i>-regulatory element containing these two SNPs and should be the regulatory target. Chromatin immunoprecipitation suggests that transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) can bind the rs17726078 surrounding region. Knock-out of the segment containing these two SNPs by CRISPR/Cas9 can significantly increase <i>DLX2</i> mRNA and protein expression, cell proliferation, colony formation, migration, and wound healing, thus suggesting that the <i>cis</i>-regulatory element is an attenuator for gene expression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>rs2357322 and rs17726078 might influence <i>DLX2</i> expression and further contribute to breast cancer risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/3096873","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148754052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation and Audit of Mainstream Genetic Testing Within a High-Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion","authors":"Soraya Conroy,&nbsp;Emma Keane,&nbsp;Bushra Rehman,&nbsp;Eleanor Wyborn,&nbsp;Catherine Brown,&nbsp;Lamb Chen,&nbsp;Josh Chatten,&nbsp;Elijah Durston-Rand,&nbsp;Blaise Sheehan,&nbsp;Elizabeth Ferguson,&nbsp;Tracie Miles,&nbsp;Emma Beck,&nbsp;Alison Hunter-Smith,&nbsp;Christiana Laban,&nbsp;Katherine Smith,&nbsp;Diana Dalgliesh,&nbsp;Rebecca Bowen,&nbsp;Nicola Laurence","doi":"10.1155/tbj/2657384","DOIUrl":"10.1155/tbj/2657384","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>It is estimated that 5%–10% of patients who develop breast cancer have a causative inherited pathogenic or likely pathogenic variant (P/LP variant). In 2020, the UK National Test Directory published criteria for mainstream genetic testing for breast cancer patients (R208) and, subsequently, eligibility criteria to determine which patients are eligible for gene testing and PARP inhibitor treatment (R444.1).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the clearly defined criteria from NHS genomics, eligibility for testing under R208/R444.1 was determined for all patients diagnosed with breast cancer between March 2021 and March 2025. Eligible patients were offered genetic testing. Incidence of P/LP variants and impact on treatment were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1812 patients had new DCIS/invasive breast cancer diagnoses, 255 were eligible for testing and 196 consented. Of these, 28 patients (14.3%) had a P/LP variant. Eight of these patients were eligible only using family history criteria. Twenty-one patients were eligible for breast conservation surgery. Preoperative genetic results were available for 13: eight patients opted for bilateral mastectomy rather than breast conservation. Where results were available postoperatively, three of eight patients who had breast conservation are planning bilateral risk reducing surgery. Three women newly diagnosed with a BRCA variant received a PARP inhibitor. Eligibility assessment for testing was time-consuming for trained clinicians.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>14.3% of patients eligible and tested for a breast cancer–related hereditary P/LP variant were positive, which aligns with the expected number predicted by Genomics England. Family history scoring is an important element. Positive results were associated with changes in surgical decision-making for 14 women and enabled 3 patients to receive a PARP inhibitor.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148594732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified Nipple Correction Surgery Combined With Debridement for Refractory Nonpuerperal Mastitis: A Clinical Study","authors":"Bing Wang,&nbsp;Jiachen Xu,&nbsp;Yue Zhou,&nbsp;Meina Ye","doi":"10.1155/tbj/8818284","DOIUrl":"10.1155/tbj/8818284","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>In refractory nonpuerperal mastitis, the treatment for fistulas requires surgeries or techniques that not only remove the lesion but also correct the inverted nipple. To improve the stability of nipple correction, Dr. Ye Meina modified the conventional technique and combined it with the fistula incision and debridement surgery to treat fistulas in refractory plasma cell mastitis (PCM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study evaluated 12 female patients with a refractory history of PCM. All patients received fistula incision and debridement combined with modified nipple correction surgery. Clinical data, including patient information, treatment effects, adverse effects, and breast appearance, were collected, and all directional information has been de-identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Follow-up was 8–39 months. The average age of all participants was 37.1 ± 7.45 years old. All patients accepted this surgery, and postoperative pathology matched the manifestation of acute or chronic PCM. The cure rate and effective rate of these patients both reached 100% (12/12), and the recurrence rate was 0% (0/12). One patient (8.3%) encountered nipple inversion recurrence. For adverse events, two reported scar formation, and one reported reversible abnormal nipple sensation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The fistula incision and debridement combined with modified nipple correction could treat refractory PCM effectively by facilitating the suture removal, reducing postoperative discomfort for patients, and making smaller surgical incisions possible. Consequently, this modified surgery has shown preliminary favorable results and warrants further investigation to determine generalizability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148594811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum IL2Rα as a Diagnostic Biomarker and Its Functional Interplay With IL-2 in Breast Cancer","authors":"Wei Wang,&nbsp;Jun Liu,&nbsp;Yun Wei,&nbsp;Yan Fang,&nbsp;Shuning Ding,&nbsp;Deyue Liu,&nbsp;Li Zhu","doi":"10.1155/tbj/5295439","DOIUrl":"10.1155/tbj/5295439","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is a leading female malignancy, with chronic inflammation driving progression. The IL-2/IL-2R axis regulates immunity, but IL2RA’s role in breast cancer (expression, diagnostic/prognostic value, and interplay with IL-2) is unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 252 consecutive patients (99 breast cancer and 153 benign breast disease) who received breast surgery were retrospectively analyzed. Serum cytokines were measured via electrochemiluminescence immunoassay; ROC, single-cell sequencing, and bioinformatics databases (TIMER and Kaplan–Meier plotter) were used to assess IL2RA/IL-2’s utility and associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Serum IL2Rα was higher in breast cancer (336.9 vs. 275.8 U/mL, <i>p</i> &lt; 0.001; no significant differences were observed for other cytokines). IL2Rα showed moderate diagnostic performance (AUC = 0.650, cut-off = 240.5 U/mL), correlated with NLR (<i>p</i> = 0.012), and showed a trend towards poor survival (<i>p</i> = 0.124, HR = 0.309, 95% CI: 0.069–1.381). Single-cell sequencing identified T cells as the primary source of IL2Rα in tumor tissues. High IL2RA expression strongly correlated with infiltration of immune cells, especially neutrophils (<i>r</i> = 0.673) and dendritic cells (<i>r</i> = 0.706). RNA-seq analysis showed IL2RA was upregulated in tumor tissues, associated with poor prognosis (<i>p</i> = 9.7<i>e</i> − 06, HR = 1.29, 95% CI: 1.15–1.44) and aggressive features (e.g., lymph node metastasis and HER2 positivity). In contrast, IL-2 was highly expressed in normal tissues, linked to better prognosis (<i>p</i> = 0.001, HR = 0.83, 95% CI: 0.74–0.93), and had opposing clinical correlations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Serum IL2Rɑ could serve as a complementary auxiliary diagnostic biomarker for breast cancer, with associations with systemic inflammation, immune cell infiltration, and aggressive disease. The functional antagonism between IL2RA and IL-2 highlights the IL-2/IL2RA axis as a critical regulator of breast cancer pathophysiology, supporting its potential as a therapeutic target for improving breast cancer diagnosis and treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148563976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple-Negative Breast Cancer","authors":"Tamasine Khadrouche,&nbsp;Mathilde Morisseau,&nbsp;Gabrielle Selmes,&nbsp;Charlotte Vaysse,&nbsp;Camille Franchet,&nbsp;Carole Massabeau,&nbsp;Mony Ung,&nbsp;Eleonora De Maio,&nbsp;Jean-Louis Lacaze,&nbsp;Eva Jouve","doi":"10.1155/tbj/5534220","DOIUrl":"https://doi.org/10.1155/tbj/5534220","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Neoadjuvant immunochemotherapy (NAIC) combining chemotherapy and pembrolizumab is now standard for Stage II-III TNBC. This study evaluates the impact of NAIC on surgical outcomes versus neoadjuvant chemotherapy (NAC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort study included 117 Stage II-III TNBC patients treated with NAIC or NAC (October 2019–May 2023). Surgical complications, time to surgery, time to radiotherapy, and pathologic response were assessed. Complications were classified using the Clavien–Dindo scale; immune-related adverse events (irAEs) followed the 2017 CTCAE criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 117 patients, 59 received NAIC and 58 NAC. Chemotherapy-related adverse events were similar (NAIC: 78.0%, NAC: 75.9%). irAEs occurred in 50.8% of NAIC patients, with 8.5% experiencing severe irAEs. Surgical complications were more frequent in NAIC (27.1%) than NAC (17.2%), though not statistically significant; seroma was the most common. Delays &gt; 12 weeks in initiating radiotherapy were more frequent in NAIC (10.7%) than NAC (0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>NAIC did not significantly increase postoperative complications compared to NAC. However, irAEs and potential treatment delays warrant careful management. Despite these risks, NAIC remains a viable option for early TNBC with manageable surgical outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/5534220","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148467441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pivotal Factors in Breast Cancer Molecular Subtypes Apoptosis Induction by ELF-EMF; Ki-67, ROS Level, HER-2, and SODs","authors":"Mohadeseh Shayeghan,&nbsp;Fatemeh Shahriari,&nbsp;Fatemeh Afroughi,&nbsp;Flora Forouzesh,&nbsp;Mohammad Hadi Niakan,&nbsp;Mohammad Amin Javidi","doi":"10.1155/tbj/9572421","DOIUrl":"https://doi.org/10.1155/tbj/9572421","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although increasing research has shown that extremely low-frequency electromagnetic fields (ELF-EMFs) specifically trigger PCD through the elevation of ROS levels in cancer cells, there is no adequate evidence to determine the exact mechanisms of this phenomenon. The antioxidant machinery may play a crucial role in this area; however, this has been neglected in previous research.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The main aim of this study was to assess the effect of ELF-EMF exposure (5 days, 1 Hz, 100 mT, 2 h/day) on ROS levels, expression levels of antioxidant genes, and apoptosis induction in different breast cancer molecular subtypes with different p53 statuses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>DCFH-DA results revealed that the ROS level increased in all three cell lines (SKBR-3, MDA-MB-231, and MCF-7); this increase was much greater in SKBR-3 (up to 5-fold compared to its sham exposure). This result was concurrent with the annexin V/PI results; SKBR-3 cells showed much more apoptosis induction (about 78%), compared with the others (22% or 11% in the other two cells). On the other hand, the mRNA expression level of SOD1 and SOD2 increased significantly in the MDA-MB-231, in addition to these two genes, the expression level of SOD3 and GSR increased in the MCF-7 cells but not in the SKBR-3.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Taken together, our results confirmed that ELF-EMF induced ROS-dependent apoptosis, especially in HER-2-enriched breast cancer cells (the SKBR-3), in a p53-independent manner. Other molecular subtypes (MDA-MB-231 as TNBC, or MCF-7 as luminal A) showed resistance against the ROS level increasing and subsequent apoptosis induction by using antioxidant genes, especially SOD1.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9572421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148467442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complications, Functional Recovery, and Quality of Life in Breast Cancer Patients Undergoing Axillary Surgery","authors":"Monica Pellegrino,&nbsp;Francesco Ioppolo,&nbsp;Monia Ranalli,&nbsp;Michelangelo Miccini,&nbsp;Francesca La Rovere,&nbsp;Stefania Lancia,&nbsp;Stefano Avenia,&nbsp;Paolo Izzo,&nbsp;Giulia Montagner,&nbsp;Giuliano D’Onghia,&nbsp;Andrea Polistena","doi":"10.1155/tbj/1469203","DOIUrl":"10.1155/tbj/1469203","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Survivorship considerations have gained increasing importance in patients with early breast cancer. Every surgical procedure poses a risk of complications and a potential negative impact on patient-reported outcomes (PROs), thereby driving growing interest in de-escalation strategies in breast cancer surgery. In this context, we aimed to assess complication rates, the potential role of physiatric rehabilitation in managing these complications, and the impact of axillary surgery on PROs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This retrospective single-center cohort study included breast cancer patients who underwent surgery between January 2022 and March 2023 at the Breast Unit of Policlinico Umberto I, Rome. Among 164 patients operated on during the study period, 71 who underwent axillary surgery and received postoperative physiatric evaluation according to the institutional care pathway (PDTA) were included. The Disability of the Arm, Shoulder and Hand (DASH) questionnaire was administered to evaluate PROs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among the included patients (&lt;i&gt;n&lt;/i&gt; = 71), SLNB was performed in 71.83% and ALND in 21.13%. A total of 34/71 patients (47.89%) developed complications requiring rehabilitative treatment and were classified as cases, while the remaining patients constituted the control group. Overall, shoulder painful mobility limitation (56.34%) (SPML), motor deficit (54.93%) (MD), and sensory deficit (46.48%) (SD) were the most frequent complications, whereas lymphedema (LE) and scapular winging (SW) occurred in 4.23% each. More extensive axillary procedures were associated with a higher number of lymph nodes removed (&lt;i&gt;p&lt;/i&gt; &lt; 0.0001). Cases had significantly more lymph nodes removed than controls (&lt;i&gt;p&lt;/i&gt; = 0.0003). Patients requiring rehabilitation were younger on average than controls. Recovery time differed significantly between cases and controls (&lt;i&gt;p&lt;/i&gt; &lt; 0.0001), with most patients recovering within 3 months from the first physiatric visit. DASH scores were significantly worse in patients requiring rehabilitative treatment than in controls (&lt;i&gt;p&lt;/i&gt; &lt; 0.0001). The mean DASH score was 14%. Higher DASH values were associated with postoperative complications requiring rehabilitation and delayed or absent recovery, particularly SPML, DM, DS, and SW.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Functional impairment of the upper limb remained frequent and may affect patients’ daily activities. These findings support the importance of integrating surgical mana","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/1469203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Plasma Circular RNAs hsa_circ_0001785 and hsa_circ_0079876 as Promising Noninvasive Diagnostic Biomarkers for Breast Cancer: A Case–Control Study","authors":"Amirhossein Sangi Nasab Lahijan,&nbsp;Sepideh Abdollahi,&nbsp;Seyed Rohollah Miri,&nbsp;Ghasem Azizi-Tabesh,&nbsp;Mir Saeed Yekaninejad,&nbsp;Pantea Izadi","doi":"10.1155/tbj/8008795","DOIUrl":"10.1155/tbj/8008795","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Breast cancer (BC) is a major health concern for women, with early diagnosis essential for better health outcomes such as survival. While mammography is the gold standard screening tool, it is not without drawbacks. Circular RNAs (circRNAs), a class of noncoding RNAs, characterized by covalently closed loops missing 5′ and 3′ ends, offer stability in body fluids like plasma and are emerging as promising diagnostic biomarkers. Thus, the aim of this study was to investigate the plasma levels of hsa_circ_0001785 and hsa_circ_0079876 in BC patients compared to healthy controls to evaluate their potential for noninvasive BC detection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 129 women participated in this study (81 BC patients who underwent surgery and 48 healthy controls based on mammography). The plasma levels of hsa_circ_0001785 and hsa_circ_0079876 were measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) following RNA extraction from plasma samples. The diagnostic value was assessed using the receiver operating characteristic (ROC) curve.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significant increase in the expression of both circRNAs was observed in BC patients compared with healthy controls (<i>p</i> value &lt; 0.001). ROC curve analysis demonstrated that an area under the curve (AUC) for hsa_circ_0001785, hsa_circ_0079876, and their combination were 0.76 (sensitivity = 74%, specificity = 79%), 0.98 (sensitivity = 93%, specificity = 92%), and 0.98 (sensitivity = 93%, specificity = 92%), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Plasma levels of hsa_circ_0001785 and hsa_circ_0079876 are significantly elevated in BC patients, with hsa_circ_0079876 showing superior sensitivity and specificity compared to hsa_circ_0001785. These findings highlight hsa_circ_0079876 as a particularly promising diagnostic potential in a case–control setting for noninvasive BC detection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/8008795","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review and Meta-Analysis: Association Between Circulating and Tissue Levels of Selenium and Zinc and Breast Cancer Risk","authors":"Adrienne Pratti Lucarelli,&nbsp;Maria Marta Martins,&nbsp;Mariana Mie Teruya,&nbsp;Thaís Tiemi Yauti,&nbsp;Daniela Rie Hayashi","doi":"10.1155/tbj/7448703","DOIUrl":"10.1155/tbj/7448703","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Selenium (Se) and zinc (Zn) are essential micronutrients that play roles in antioxidant defense and the regulation of cell proliferation. Increasing evidence suggests that disturbances in trace element balance may contribute to breast carcinogenesis; however, findings across studies remain inconsistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the association between circulating and tissue Se and Zn levels and breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review and meta-analysis were conducted according to PRISMA 2020 and MOOSE recommendations. Searches were performed in MedLine, EMBASE, and LILACS from database inception until April 15, 2026. Case–control studies comparing selenium and zinc levels between women with breast cancer and control groups were eligible. Two independent reviewers performed study selection, data extraction, risk-of-bias assessment, and publication bias analysis using Egger’s regression test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty case–control studies were included. Most studies (83.3%) were classified as high methodological quality according to the Newcastle–Ottawa Scale. Meta-analyses revealed significantly lower selenium levels in plasma (MD = −12.10 μg/L; 95% CI: −17.54 to −6.65; <i>p</i> &lt; 0.0001), selenium in nails (MD = −0.02 μg/g; 95% CI: −0.04 to −0.01; <i>p</i> = 0.006), and zinc in plasma (MD = −0.33; 95% CI: −0.47 to −0.19; <i>p</i> &lt; 0.00001) in breast cancer patients compared with controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The pooled findings indicate an inverse association between breast cancer and selenium levels measured in plasma and nails, as well as plasma zinc concentrations. Nevertheless, interpretation should remain cautious because all included studies had observational designs, with marked heterogeneity and potential residual confounding. Lower circulating selenium and zinc levels, together with reduced selenium concentrations in nails, were associated with breast cancer occurrence. Additional prospective studies are required to clarify causality and determine the clinical significance of these associations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7448703","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148370960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}